INVO Bioscience closes $3M offering with warrants exercisable at $0.63

INVO Fertility, Inc.

Gross proceeds of ~$3.0M from sale of 3,680,000 shares (or pre-funded warrants) and 5,520,000 warrants.
Warrants exercisable immediately at $0.63/share, expire in eight years.
Net proceeds to repay up to $500K convertible debentures (at 105%) and fund acquisition down payment for Wisconsin Facility Institute.
Placement agent Maxim Group LLC received 5.0% fee and warrants for 147,200 shares at $0.8965.
Officers and directors subject to 180-day lock-up on equity transactions.

item 1.01 item 2.04 item 3.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

INVO Fertility, Inc. entered into Placement Agency Agreement with Maxim Group LLC (effective 2023-03-23).

Action: entry
Agreement: underwriting
Counterparty: Maxim Group LLC
Effective: 2023-03-23

Exact text from the filing

Also in connection with the offering, on March 23, 2023, the Company entered into a placement agency agreement (the “Placement Agency Agreement”) with Maxim Group LLC

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

INVO Fertility, Inc. entered into Purchase Agreement with certain institutional investors (effective 2023-03-23).

Action: entry
Agreement: equity purchase
Counterparty: certain institutional investors
Effective: 2023-03-23

Exact text from the filing

On March 23, 2023, INVO Bioscience, Inc., a Nevada corporation (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors

View on SEC.gov

250 material agreements filed in the last 30 days. Browse all material agreements →

INVO Fertility, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-009222

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.